Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinica...
All content for Evaluating Biopharma is the property of Evaluating Biopharma and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinica...
Episode: 23 - An Industry Veteran’s Insight on Data Governance and Provenance
Evaluating Biopharma
16 minutes
1 year ago
Episode: 23 - An Industry Veteran’s Insight on Data Governance and Provenance
In this episode of Evaluating Biopharma, host Ben Locwin and Scott Endicott, executive leader of Healthcare Solutions Integration, talk about data governance and data provenance—why they matter and how the industry can achieve them. With 30 years of experience, Endicott has a deep understanding of training AI and ML models, particularly when patient data is included, and offers advice on how to navigate the challenges of data governance and provenance in the near-term future. Links from...
Evaluating Biopharma
Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinica...
